Frequently Asked Questions
In 2022, the market for mast cell stabilizers was estimated to be worth USD 1948.5 million.
The market for mast cell stabilizers is anticipated to increase at a CAGR of 6.80% from 2023 to 2030, reaching USD 3298.15 million in 2030.
Oral medications are the most popular category of product type.
Asthma, by the indication, is the notable segment.
During the projection period, the hospital pharmacies category is anticipated to exhibit the highest CAGR.
The mast cell stabilizers market was ruled by North America.
The top players include Viatris, Bausch & Lomb Incorporated, AbbVie, Inc., Merck KGaA, Celltech Pharmaceuticals, Inc., Alcon Laboratories, Inc., Akorn, Inc., and others.
Attempts to boost patient adherence to treatment plans as well as increased exposure to allergens as a result of increased international travel and trade. These are the key drivers influencing the expansion of the global market.
The challenges limiting the growth of the mast cell stabilizers market are long-term use concerns, generic competition, limited indications, and allergen avoidance.
The most significant market advancements in this sector include the shift from prescription-only to over-the-counter (OTC) medications for a number of treatments. This procedure of moving from a prescription-only to an OTC medicine has many benefits. For businesses operating in this market, these new developments are anticipated to provide access to a new patient population base and significantly boost market growth throughout the forecast period.